Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

A need for implementation science to optimise the use of evidence-based interventions in HIV care: A systematic literature review.

Cox J, Gutner C, Kronfli N, Lawson A, Robbins M, Nientker L, Ostawal A, Barber T, Croce D, Hardy D, Jessen H, Katlama C, Mallolas J, Rizzardini G, Alcorn K, Wohlfeiler M, Le Fevre E.

PLoS One. 2019 Aug 19;14(8):e0220060. doi: 10.1371/journal.pone.0220060. eCollection 2019.

2.

Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naïve HIV-1 Infected Adults with Transmitted Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance Mutations.

Wong A, Goldstein D, Mallolas J, DeJesus E, Johnson M, Molina JM, Pozniak A, Rodgers A, Teal V, Hepler D, Kumar S, Sklar P, Hanna GJ, Hwang C, Badshah C, Teppler H.

J Acquir Immune Defic Syndr. 2019 Aug 16. doi: 10.1097/QAI.0000000000002153. [Epub ahead of print] No abstract available.

PMID:
31425317
3.

A 24-week pilot study of dual maintenance therapy with raltegravir plus lamivudine.

de Lazzari E, Lonca M, Rojas J, Gonzalez-Cordon A, Blanch J, Inciarte A, Tricas A, Rodriguez A, Martinez-Rebollar M, Laguno M, Mallolas J, Sanchez-Palomino S, Plana M, Blanco JL, Martinez E.

AIDS. 2019 Jul 22. doi: 10.1097/QAD.0000000000002311. [Epub ahead of print]

PMID:
31335805
4.

Barriers to hepatitis C virus elimination in MSM living with HIV: The high risk of reinfection. Case study: A patient with 6 episodes.

Laguno M, Martínez-Rebollar M, de la Mora L, Pérez-Del-Pulgar S, Mallolas J.

Gastroenterol Hepatol. 2019 Jul 16. pii: S0210-5705(19)30132-3. doi: 10.1016/j.gastrohep.2019.04.005. [Epub ahead of print] English, Spanish. No abstract available.

PMID:
31324465
5.

Metabolic, mitochondrial, renal and hepatic safety of enfuvirtide and raltegravir antiretroviral administration: Randomized crossover clinical trial in healthy volunteers.

Barroso S, Morén C, González-Segura À, Riba N, Arnaiz JA, Manriquez M, Santana G, Blanco JL, Larousse M, Loncà M, Lazzari E, Llopis J, Mallolas J, Miró O, Carné X, Gatell JM, Garrabou G, Martínez E.

PLoS One. 2019 May 23;14(5):e0216712. doi: 10.1371/journal.pone.0216712. eCollection 2019.

6.

Cholangitis and pulmonary nodules in a clinical presentation of syphilis in an HIV-infected patient.

Hermida-Lama E, Marco-Hernández J, Medaglia AA, Pagès M, Vollmer I, Ramírez J, Martínez D, Mallolas J, García F.

Int J STD AIDS. 2019 Jul;30(8):820-824. doi: 10.1177/0956462418823386. Epub 2019 May 2. No abstract available.

PMID:
31046616
7.

Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.

Johnson M, Kumar P, Molina JM, Rizzardini G, Cahn P, Bickel M, Mallolas J, Zhou Y, Morais C, Kumar S, Sklar P, Hanna GJ, Hwang C, Greaves W; DRIVE-SHIFT Study Group.

J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472. doi: 10.1097/QAI.0000000000002056.

PMID:
30985556
8.

Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.

Maduell F, Belmar L, Ugalde J, Laguno M, Martínez-Rebollar M, Ojeda R, Arias M, Rodas L, Rossi F, Llovet LP, González LN, Mallolas J, Londoño MC.

Gastroenterol Hepatol. 2019 Mar;42(3):164-170. doi: 10.1016/j.gastrohep.2018.07.015. Epub 2018 Oct 4. English, Spanish.

PMID:
30293914
9.

A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity.

Rojas J, Blanco JL, Sanchez-Palomino S, Marcos MA, Guardo AC, Gonzalez-Cordon A, Lonca M, Tricas A, Rodriguez A, Romero A, Miro JM, Mallolas J, Gatell JM, Plana M, Martinez E.

AIDS. 2018 Jul 31;32(12):1633-1641. doi: 10.1097/QAD.0000000000001843.

PMID:
29746294
10.

Subclinical cardiovascular disease in patients starting contemporary protease inhibitors.

González-Cordón A, Doménech M, Camafort M, Martínez-Rebollar M, Torres B, Laguno M, Rojas J, Loncà M, Blanco JL, Mallolas J, Gatell JM, de Lazzari E, Martínez E.

HIV Med. 2018 May 10. doi: 10.1111/hiv.12619. [Epub ahead of print]

PMID:
29745457
11.

Full blood count values as a predictor of poor outcome of pneumonia among HIV-infected patients.

Camon S, Quiros C, Saubi N, Moreno A, Marcos MA, Eto Y, Rofael S, Monclus E, Brown J, McHugh TD, Mallolas J, Perello R.

BMC Infect Dis. 2018 Apr 19;18(1):189. doi: 10.1186/s12879-018-3090-0.

12.

Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.

Blanco JL, Rojas J, Paredes R, Negredo E, Mallolas J, Casadella M, Clotet B, Gatell JM, de Lazzari E, Martinez E; DOLAM Study Team .

J Antimicrob Chemother. 2018 Jul 1;73(7):1965-1971. doi: 10.1093/jac/dky093.

PMID:
29608685
13.

Pharmacokinetic analysis of nevirapine extended release 400 mg once daily vs nevirapine immediate release 200 mg twice daily formulation in treatment-naïve patients with HIV-1 infection.

Yong CL, Gathe JC, Knecht G, Orrell C, Mallolas J, Podzamczer D, Trottier B, Zhang W, Sabo JP, Vinisko R, Drulak M, Quinson AM.

HIV Clin Trials. 2017 Nov-Dec;18(5-6):189-195. doi: 10.1080/15284336.2017.1386811.

PMID:
29210627
14.

Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.

Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group.

J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246.

PMID:
29091217
15.

Darunavir Stands Up as Preferred HIV Protease Inhibitor.

Mallolas J.

AIDS Rev. 2017 Apr - Jun;19(2):105-112. Review.

PMID:
28664942
16.

Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing.

Caro-Pérez N, Martínez-Rebollar M, Gregori J, Quer J, González P, Gambato M, García-González N, González-Candelas F, Costa J, Esteban JI, Mallolas J, Forns X, Laguno M, Pérez-Del-Pulgar S.

J Clin Virol. 2017 Jul;92:42-47. doi: 10.1016/j.jcv.2017.05.008. Epub 2017 May 10.

PMID:
28521213
17.

Tolerability of integrase inhibitors in a real-life setting.

Peñafiel J, de Lazzari E, Padilla M, Rojas J, Gonzalez-Cordon A, Blanco JL, Blanch J, Marcos MA, Lonca M, Martinez-Rebollar M, Laguno M, Tricas A, Rodriguez A, Mallolas J, Gatell JM, Martinez E.

J Antimicrob Chemother. 2017 Jun 1;72(6):1752-1759. doi: 10.1093/jac/dkx053.

PMID:
28333231
18.

Eradication of hepatitis C virus and non-liver-related non-acquired immune deficiency syndrome-related events in human immunodeficiency virus/hepatitis C virus coinfection.

Berenguer J, Rodríguez-Castellano E, Carrero A, Von Wichmann MA, Montero M, Galindo MJ, Mallolas J, Crespo M, Téllez MJ, Quereda C, Sanz J, Barros C, Tural C, Santos I, Pulido F, Guardiola JM, Rubio R, Ortega E, Montes ML, Jusdado JJ, Gaspar G, Esteban H, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group.

Hepatology. 2017 Aug;66(2):344-356. doi: 10.1002/hep.29071. Epub 2017 Jun 22.

19.

Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.

Saumoy M, Tiraboschi JM, Ordoñez-Llanos J, Ribera E, Domingo P, Mallolas J, Curto J, Gatell JM, Podzamczer D.

HIV Clin Trials. 2017 Mar;18(2):49-53. doi: 10.1080/15284336.2016.1275425. Epub 2017 Jan 12.

PMID:
28081673
20.

Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study.

Laguno M, Von Wichmann MA, Van den Eynde E, Navarro J, Cifuentes C, Murillas J, Veloso S, Martínez-Rebollar M, Guardiola JM, Jou A, Gómez-Sirvent JL, Cervantes M, Pineda JA, López-Calvo S, Carrero A, Montes ML, Deig E, Tapiz A, Ruiz-Mesa JD, Cruceta A, de Lazzari E, Mallolas J.

Int J Infect Dis. 2016 Dec;53:46-51. doi: 10.1016/j.ijid.2016.10.028. Epub 2016 Nov 1.

21.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

Nicolás D, Esteve A, Cuadros A, Campbell CNJ, Tural C, Podzamczer D, Murillas J, Homar F, Segura F, Force L, Vilaró J, Masabeu À, Garcia I, Mercadal J, Montoliu A, Ferrer E, Riera M, Cifuentes C, Ambrosioni J, Navarro G, Manzardo C, Clotet B, Gatell JM, Casabona J, Miró JM; PISCIS Cohort Study Investigators, Murillas J, Manzardo C, Masabeu A, Mercadal J, Cifuentes C, Dalmau D, Domingo P, Falcó V, Curran A, Agustí C, Montoliu A, Pérez I, Curto J, Gargoulas F, Gómez A, Rubia JC, Zamora L, Blanco JL, Garcia-Alcaide F, Martínez E, Mallolas J, Llibre JM, Sirera G, Romeu J, Jou A, Negredo E, Saumoy M, Imaz A, Bolao F, Cabellos C, Peña C, DiYacovo S, Van Den Eynde E, Sala M, Cervantes M, Amengual MJ, Navarro M, Segura V, Barrufet P, Molina J, Alvaro M, Payeras T, Gracia Mateo M, Fernández J.

Clin Infect Dis. 2016 Jun 15;62(12):1578-1585. doi: 10.1093/cid/ciw157. Epub 2016 Apr 28.

PMID:
27126346
22.

Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.

Crespo M, Navarro J, Martinez-Rebollar M, Podzamczer D, Domingo P, Mallolas J, Saumoy M, Mateo GM, Curran A, Gatell J, Ribera E.

HIV Clin Trials. 2016 May;17(3):89-95. doi: 10.1080/15284336.2016.1149929. Epub 2016 Mar 16.

PMID:
27125363
23.

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):517-23. doi: 10.1016/j.eimc.2016.02.025. Epub 2016 Apr 5. Review.

PMID:
27056581
24.

Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression.

Rojas J, Blanco JL, Marcos MA, Lonca M, Tricas A, Moreno L, Gonzalez-Cordon A, Torres B, Mallolas J, Garcia F, Gatell JM, Martinez E.

J Antimicrob Chemother. 2016 Jul;71(7):1975-81. doi: 10.1093/jac/dkw078. Epub 2016 Mar 28.

PMID:
27021341
25.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group.

J Antimicrob Chemother. 2016 Jul;71(7):1982-6. doi: 10.1093/jac/dkw048. Epub 2016 Mar 18.

PMID:
26994091
26.

A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.

Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; RALPEP Study Group.

J Antimicrob Chemother. 2016 Jul;71(7):1987-93. doi: 10.1093/jac/dkw049. Epub 2016 Mar 18.

PMID:
26994089
27.

Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015.

Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, Sanz Moreno J, Amador C, Antela A, Arazo P, Arrizabalaga J, Bachiller P, Barros C, Berenguer J, Caylá J, Domingo P, Estrada V, Knobel H, Locutura J, López Aldeguer J, Llibre JM, Lozano F, Mallolas J, Malmierca E, Miralles C, Miralles P, Muñoz A, Ocampo A, Olalla J, Pérez I, Pérez Elías MJ, Pérez Arellano JL, Portilla J, Ribera E, Rodríguez F, Santín M, Sanz Sanz J, Téllez MJ, Torralba M, Valencia E, Von Wichmann MA; GESIDA/SEIMC Writing Committee.

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11.

PMID:
26976381
28.

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.

Hepatitis C- working group for COHERE in Eurocoord, Smit C, Arends J, Peters L, Montforte Ad, Dabis F, Zangerle R, Daikos G, Mussini C, Mallolas J, de Wit S, Zinkernagel A, Cosin J, Chene G, Raben D, Rockstroh J.

BMC Infect Dis. 2015 Nov 4;15:498. doi: 10.1186/s12879-015-1224-1.

29.

Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M.

Lancet HIV. 2015 Aug;2(8):e319-27. doi: 10.1016/S2352-3018(15)00114-9. Epub 2015 Jul 9. Erratum in: Lancet HIV. 2015 Aug;2(8):e316. Lancet HIV. 2015 Oct;2(10):e416.

PMID:
26423374
30.

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group.

Lancet Infect Dis. 2015 Jul;15(7):785-92. doi: 10.1016/S1473-3099(15)00096-1. Epub 2015 Jun 7. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875.

PMID:
26062880
31.

Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.

Sulkowski M, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, Nahass R, Shibolet O, Serfaty L, Bourliere M, DeJesus E, Zuckerman E, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B.

Lancet. 2015 Mar 21;385(9973):1087-97. doi: 10.1016/S0140-6736(14)61793-1. Epub 2014 Nov 11.

PMID:
25467560
32.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

Berenguer J, Zamora FX, Aldámiz-Echevarría T, Von Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jusdado JJ, Pérez G, Díez C, Álvarez-Pellicer J, Esteban H, Bellón JM, González-García J; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group.

Clin Infect Dis. 2015 Mar 15;60(6):950-8. doi: 10.1093/cid/ciu939. Epub 2014 Nov 24.

PMID:
25422386
33.

A polymorphism in the promoter region of the survivin gene is related to hemorrhagic transformation in patients with acute ischemic stroke.

Mallolas J, Rodríguez R, Gubern C, Camós S, Serena J, Castellanos M.

Neuromolecular Med. 2014 Dec;16(4):856-61. doi: 10.1007/s12017-014-8333-7. Epub 2014 Oct 25.

PMID:
25344020
34.

[Acute outbreak of hepatitis C in human immunodeficiency virus-infected patients].

Martínez-Rebollar M, Mallolas J, Pérez I, González-Cordón A, Loncà M, Torres B, Rojas JF, Monteiro P, Blanco JL, Martínez E, Gatell JM, Laguno M.

Enferm Infecc Microbiol Clin. 2015 Jan;33(1):3-8. doi: 10.1016/j.eimc.2014.05.013. Epub 2014 Aug 12. Spanish.

PMID:
25124489
35.

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

Expert Panel of GeSIDA and the National Aids Plan, Berenguer J, Polo R, Lozano F, López Aldeguer J, Antela A, Arribas JR, Asensi V, Blanco JR, Clotet B, Domingo P, Galindo MJ, Gatell JM, González-García J, Iribarren JA, Locutura J, López JC, Mallolas J, Martínez E, Miralles C, Miró JM, Moreno S, Palacios R, Pérez Elías MJ, Pineda JA, Podzamczer D, Portilla J, Pulido F, Ribera E, Riera M, Rubio R, Santos J, Sanz J, Tuset M, Vidal F, Rivero A.

Enferm Infecc Microbiol Clin. 2014 Aug-Sep;32(7):447-58. doi: 10.1016/j.eimc.2014.02.018. Epub 2014 Jun 28.

PMID:
24986715
36.

Impact of prior virological failure and nucleos(t)ide genotypic resistance mutations on the efficacy of switching from ritonavir-boosted protease inhibitors to raltegravir.

Blanco JL, Gonzalez-Cordón A, Llibre JM, Calvo M, Gutierrez F, Podzamczer D, Laguno M, Fumero E, Murillas J, Mallolas J, Martinez-Rebollar M, Lonca M, Perez I, Gatell JM, Martinez E.

Antivir Ther. 2015;20(5):487-92. doi: 10.3851/IMP2812. Epub 2014 Jun 25.

PMID:
24964358
37.

The high-mobility group I-Y transcription factor is involved in cerebral ischemia and modulates the expression of angiogenic proteins.

Camós S, Gubern C, Sobrado M, Rodríguez R, Romera VG, Moro MA, Lizasoain I, Serena J, Mallolas J, Castellanos M.

Neuroscience. 2014 Jun 6;269:112-30. doi: 10.1016/j.neuroscience.2014.03.036. Epub 2014 Mar 27.

PMID:
24680881
38.

Characterization of Gcf2/Lrrfip1 in experimental cerebral ischemia and its role as a modulator of Akt, mTOR and β-catenin signaling pathways.

Gubern C, Camós S, Hurtado O, Rodríguez R, Romera VG, Sobrado M, Cañadas R, Moro MA, Lizasoain I, Serena J, Mallolas J, Castellanos M.

Neuroscience. 2014 May 30;268:48-65. doi: 10.1016/j.neuroscience.2014.02.051. Epub 2014 Mar 14.

PMID:
24637094
39.

Oct-2 transcription factor binding activity and expression up-regulation in rat cerebral ischaemia is associated with a diminution of neuronal damage in vitro.

Camós S, Gubern C, Sobrado M, Rodríguez R, Romera VG, Moro MÁ, Lizasoain I, Serena J, Mallolas J, Castellanos M.

Neuromolecular Med. 2014 Jun;16(2):332-49. doi: 10.1007/s12017-013-8279-1. Epub 2013 Nov 27.

PMID:
24282026
40.

Acquisition of resistant microorganisms and infections in HIV-infected patients admitted to the ICU.

Cobos-Trigueros N, Rinaudo M, Solé M, Castro P, Pumarol J, Hernández C, Fernández S, Nicolás JM, Mallolas J, Vila J, Morata L, Gatell JM, Soriano A, Mensa J, Martínez JA.

Eur J Clin Microbiol Infect Dis. 2014 Apr;33(4):611-20. doi: 10.1007/s10096-013-1995-5. Epub 2013 Oct 23.

PMID:
24150792
41.

Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.

Monteiro P, Perez I, Laguno M, Martínez-Rebollar M, González-Cordon A, Lonca M, Mallolas J, Blanco JL, Gatell JM, Martínez E.

J Antimicrob Chemother. 2014 Mar;69(3):742-8. doi: 10.1093/jac/dkt406. Epub 2013 Oct 14.

PMID:
24128667
42.

miRNA expression is modulated over time after focal ischaemia: up-regulation of miR-347 promotes neuronal apoptosis.

Gubern C, Camós S, Ballesteros I, Rodríguez R, Romera VG, Cañadas R, Lizasoain I, Moro MA, Serena J, Mallolas J, Castellanos M.

FEBS J. 2013 Dec;280(23):6233-46. doi: 10.1111/febs.12546. Epub 2013 Oct 28.

43.

Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.

Martínez-Rebollar M, Muñoz A, Pérez I, Hidalgo S, Brunet M, Laguno M, González A, Calvo M, Loncà M, Blanco JL, Martínez E, Gatell JM, Mallolas J.

Ther Drug Monit. 2013 Aug;35(4):552-6. doi: 10.1097/FTD.0b013e31828d50ef.

PMID:
23851911
44.

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.

Sulkowski M, Pol S, Mallolas J, Fainboim H, Cooper C, Slim J, Rivero A, Mak C, Thompson S, Howe AY, Wenning L, Sklar P, Wahl J, Greaves W; P05411 study investigators.

Lancet Infect Dis. 2013 Jul;13(7):597-605. doi: 10.1016/S1473-3099(13)70149-X. Epub 2013 Jun 12.

PMID:
23768747
45.

Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.

Lucero C, Torres B, León A, Calvo M, Leal L, Pérez I, Plana M, Arnedo M, Mallolas J, Gatell JM, García F.

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1161-7. doi: 10.1089/AID.2012.0367. Epub 2013 Apr 18.

46.

Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

Berenguer J, Alvarez-Pellicer J, Carrero A, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, Van Den Eynde E, Téllez MJ, Quereda C, Tural C, Sanz J, Barros C, Santos I, Pulido F, Guardiola JM, Ortega E, Rubio R, Jusdado JJ, Montes ML, Gaspar G, Barquilla E, Bellón JM, González-García J; GESIDA HIV/HCV Cohort Study Group.

J Hepatol. 2013 Jun;58(6):1104-12. doi: 10.1016/j.jhep.2013.01.042. Epub 2013 Feb 7.

PMID:
23395690
47.

A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.

McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal N, Zeuzem S, Piratvisuth T, Marcellin P, Fried MW.

Hepatology. 2013 Apr;57(4):1325-32. doi: 10.1002/hep.26246.

48.

Comparison of lymphocyte isolation methods for endoscopic biopsy specimens from the colonic mucosa.

Carrasco A, Mañe J, Santaolalla R, Pedrosa E, Mallolas J, Lorén V, Fernández M, Fernández-Bañares F, Rosinach M, Loras C, Forné M, Andújar X, Vidal J, Viver JM, Esteve M.

J Immunol Methods. 2013 Mar 29;389(1-2):29-37. doi: 10.1016/j.jim.2012.12.006. Epub 2012 Dec 30.

PMID:
23279944
49.

Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.

Vidal F, López-Dupla M, Laguno M, Veloso S, Mallolas J, Murillas J, Cifuentes C, Gallart L, Auguet T, Sampériz G, Payeras A, Hernandez P, Arnedo M, Gatell JM, Richart C.

PLoS One. 2012;7(11):e47725. doi: 10.1371/journal.pone.0047725. Epub 2012 Nov 2.

50.

Differences between HIV-infected and uninfected adults in the contributions of smoking, diabetes and hypertension to acute coronary syndrome: two parallel case-control studies.

Calvo-Sánchez M, Perelló R, Pérez I, Mateo MG, Junyent M, Laguno M, Blanco JL, Martínez-Rebollar M, Sánchez M, Mallolas J, Gatell JM, Domingo P, Martínez E.

HIV Med. 2013 Jan;14(1):40-8. doi: 10.1111/j.1468-1293.2012.01057.x. Epub 2012 Oct 22.

Supplemental Content

Loading ...
Support Center